Lead Sponsor

Celgene

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Cohort 1 and 2
•Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect® MM registry
•Age ≥18 years
•Willing and able to provide signed informed consent
•Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel
•Cohort 3
•Received 1L therapy for symptomatic active MM and subsequently has evidence of disease progression. Prior 1L MM treatment received, including anti-myeloma therapy, transplant, chemotherapy, radiation, and surgery, must be known.
•Initiated or intends to initiate 2L systemic therapy for MM after the first documented relapsed/refractory date (i.e. 1L PD).
•Enrollment date must be within 90 days of start date (or intended start date) of 2L systemic therapy.

•Cohort 1 and 2
•\- None
•Cohort 3
•Patient's 1L MM treatment was for smoldering MM or MGUS, and not for symptomatic MM
•Currently active in any MM Registry, including but not limited to, the Connect® MM registry or another Celgene/BMS-Sponsored registry.
•Currently enrolled or intending to enroll within 90 days in any interventional clinical trial in which any treatment is an investigational product that cannot be identified

Related studies

NCT07053436 · High Risk Newly Diagnosed Multiple Myeloma

NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)

NCT07030517 · Multiple Myeloma

NCT02269592 · Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, and more

NCT06106945 · Multiple Myeloma

Connect® MM- The Multiple Myeloma Disease Registry